IRVINE, Calif., April 25, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its Proove Nexus™ platform is the World's Largest DNA Pain Biobank and Big Data Clinical Data Set in Chronic Pain as it has surpassed the milestones of 100,000 specimens archived and 28 billion clinical outcome data points at the end of 2016.
Precision medicine is far more than genetics, because it involves genetic, lifestyle, environmental and behavioral information. Proove® has already used its big data set to discover algorithms that have been commercialized in clinically-proven precision medicine profiles, and Proove® continues to invest in research as the leader in the field. Proove Nexus™ is a patented system that collects, archives, and analyzes DNA specimens, along with well-characterized phenotypic data involving prospective patient-centered outcomes data on patients suffering from chronic pain (longer than 3 months). It is bigger than all of the NIH-funded registries combined, and includes genetic data.
Dr. Svetlana Kantorovich, Proove®'s R&D Director, explains, "Proove®'s research protocols and activities are approved by institutional review boards licensed by the Office of Human Research Protections at the U.S. Department of Health and Human Services. Our protocols have been approved and listed by the U.S. National Library of Medicine's web site, www.ClinicalTrials.gov." She explains further, "To implement these studies and collect this high-quality data, Proove® deploys Patient Engagement Representatives to medical practices, where they enroll patients, receive informed consents, collect data prospectively, and help clinicians with non-medical, study-related paperwork. Each PER's training far exceeds recently upgraded standards for NIH-Awardees involved in NIH-funded clinical trials as PERs are trained in HIPAA, NIH Clinical Research Training, and Good Clinical Practices (GCP)."
Discussing the potential of Proove Nexus™, Associate R&D Director, Dr. Ashley Brenton explains, "Recognizing this milestone, we're now providing researchers with access to collaborate. Our big data set is unique because we don't use unreliable data from EMRs or insurance claims that don't track outcomes well. We collect quality phenotypic data, and Proove Nexus™ grows by thousands of DNA specimens and over 3 million data points monthly. We hope to create even more collaborations that build on our existing relationships with some of the leading researchers in pain genetics."
About Proove® Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals. Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, California, Proove® has been recognized on the Inc. 500 and the Deloitte Technology Fast500 as one of the fastest growing companies in North America. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/worlds-largest-dna-biobank-and-big-data-set-in-chronic-pain-surpasses-milestone-of-100000-specimens-and-28-billion-data-points-300445273.html
SOURCE Proove Biosciences, Inc.